{"id":"NCT01527110","sponsor":"GlaxoSmithKline","briefTitle":"A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection","officialTitle":"An Open-label, Multi-centre, Single Arm Study to Evaluate the Safety and Efficacy of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Confirmed Influenza Infection (NAI115215)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-01-01","primaryCompletion":"2013-03-01","completion":"2013-03-29","firstPosted":"2012-02-06","resultsPosted":"2018-02-22","lastUpdate":"2018-02-22"},"enrollment":21,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Influenza, Human"],"interventions":[{"type":"DRUG","name":"Intravenous (IV) zanamivir","otherNames":[]}],"arms":[{"label":"Intravenous (IV) zanamivir 600mg twice daily","type":"EXPERIMENTAL"}],"summary":"This study will be an open-label, multi-center, single arm study to evaluate the safety and efficacy of IV zanamivir 600mg twice daily for 5 days in hospitalized subjects with laboratory confirmed influenza infection.","primaryOutcome":{"measure":"Number of Participants With Any Adverse Event (AE), Drug-related AE, Grade 3 and Grade 4 AE, Grade 3 and 4 Drug-related AE , AE Leading to Discontinuation of Study Drug or From Study, Serious AE (SAE), Drug-related SAE, Fatal AE and Drug-related Fatal AE","timeFrame":"Start of treatment (Day 1) up to follow-up (Day 33)","effectByArm":[{"arm":"Zanamivir 600 mg BID","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":7,"countries":["Japan"]},"refs":{"pmids":["25470818"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":21},"commonTop":["Diarrhoea","Pyrexia"]}}